• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

Spiro[5,7-dihydropyrazolo[5,1-b][1,3]oxazine-6,1'-cyclobutane]-2-carboxylic acid (CAS No. 1707365-33-0): A Comprehensive Overview in Modern Chemical Biology and Medicinal Chemistry

Spiro[5,7-dihydropyrazolo[5,1-b][1,3]oxazine-6,1'-cyclobutane]-2-carboxylic acid, identified by its unique Chemical Abstracts Service (CAS) number 1707365-33-0, represents a structurally intriguing compound that has garnered significant attention in the realms of chemical biology and medicinal chemistry. This spirocyclic scaffold, characterized by its intricate heterocyclic arrangement, combines a pyrazole ring with an oxazine moiety linked through a cyclobutane bridge. Such structural complexity often translates into a rich pharmacophoric potential, making it a promising candidate for further exploration in drug discovery and molecular research.

The compound's nomenclature adheres to the IUPAC system, precisely describing its fused ring system and functional groups. The presence of a carboxylic acid group at the 2-position of the spirocyclic structure not only confers acidic properties but also opens avenues for further derivatization and bioconjugation strategies. These features are particularly relevant in the context of developing novel therapeutic agents where functional group compatibility is a critical determinant of biological activity and pharmacokinetic properties.

In recent years, there has been a surge in interest regarding heterocyclic compounds due to their prevalence in bioactive natural products and synthetic drugs. The Spiro[5,7-dihydropyrazolo[5,1-b][1,3]oxazine-6,1'-cyclobutane]-2-carboxylic acid scaffold exemplifies this trend, as it integrates multiple pharmacologically relevant moieties within a single molecular framework. The pyrazole ring is well-known for its role in various bioactivities, including anti-inflammatory, antimicrobial, and anticancer effects. Meanwhile, the oxazine ring can contribute to metabolic stability and binding affinity at biological targets.

The spirocyclic core itself introduces rigidity to the molecule, which can be advantageous in optimizing interactions with biological receptors or enzymes. This structural motif has been employed in various drug candidates to enhance binding specificity and reduce off-target effects. Furthermore, the cyclobutane ring can serve as a conformational constraint, helping to stabilize the active conformation of the molecule when bound to a target protein or nucleic acid.

Recent advancements in computational chemistry and molecular modeling have facilitated the virtual screening of vast chemical libraries to identify promising candidates like Spiro[5,7-dihydropyrazolo[5,1-b][1,3]oxazine-6,1'-cyclobutane]-2-carboxylic acid. These computational approaches leverage quantum mechanics-based methods and machine learning algorithms to predict binding affinities and identify potential drug-like properties. Such high-throughput virtual screening has accelerated the discovery process by allowing researchers to prioritize compounds based on their predicted efficacy and safety profiles.

The synthesis of complex heterocyclic compounds like Spiro[5,7-dihydropyrazolo[5,1-b][1,3]oxazine-6,1'-cyclobutane]-2-carboxylic acid remains a challenging yet fascinating aspect of organic chemistry. Modern synthetic strategies often involve multi-step cascades that exploit transition metal catalysis to achieve complex bond formations efficiently. For instance, palladium-catalyzed cross-coupling reactions have been instrumental in constructing the spirocyclic core by facilitating the formation of carbon-carbon bonds between the pyrazole and oxazine moieties.

Additionally, asymmetric synthesis techniques have enabled the preparation of enantiomerically pure forms of such compounds, which is crucial for evaluating their stereochemical specificity in biological assays. The development of novel synthetic methodologies not only broadens the synthetic toolbox but also enhances our ability to access structurally diverse libraries for drug discovery campaigns.

The biological evaluation of Spiro[5,7-dihydropyrazolo[5,1-b][1,3]oxazine-6,1'-cyclobutane]-2-carboxylic acid has been hampered by limited availability of sufficient quantities for extensive preclinical studies. However， preliminary in vitro assays have shown promising activity against certain disease-relevant targets. For instance， early investigations have suggested that this compound may exhibit inhibitory effects on specific kinases or enzymes implicated in cancer progression. These findings align with the broader interest in targeting aberrant signaling pathways using small-molecule inhibitors.

The carboxylic acid functionality at the 2-position presents an opportunity for further functionalization to enhance bioavailability or improve target engagement. Strategies such as esterification or amide coupling could be employed to modify this group while preserving or enhancing biological activity. Moreover， bioconjugation techniques could be utilized to link this compound to other biomolecules like antibodies or peptides for targeted therapy applications.

The role of Spiro[5,7-dihydropyrazolo[5,1-b][1,3]oxazine-6,1'-cyclobutane]-2-carboxylic acid as a building block for more complex derivatives cannot be overstated. Its unique scaffold provides a versatile platform for generating novel molecules with tailored properties through medicinal chemistry interventions. By leveraging structure-activity relationship (SAR) studies， researchers can iteratively optimize potency， selectivity， and pharmacokinetic profiles.

The integration of genomics， proteomics， and metabolomics data has further enhanced our understanding of how compounds like Spiro[5 ,7 -dih ydrop yraz ol o [ 5 , 1 -b ] [ 13 ] ox az ine -6 , 11 '- cyc lob ut an e ] -2 -car box ylic ac id interact with biological systems at multiple levels。 These omics technologies enable high-content screening approaches that provide holistic insights into molecular mechanisms， thereby guiding rational drug design efforts。

In conclusion， Spiro[5 ,7 -dih ydrop yraz ol o [ 5 , 11 '-b ] [ 13 ] ox az ine -6 ,11 '- cyc lob ut an e ] -2 -car box ylic ac id ( CAS No . 17073 65 -33 -0) stands out as a structurally sophisticated compound with significant potential in chemical biology and medicinal chemistry。 Its unique spirocyclic scaffold ， combined with pharmacologically relevant heterocycles ， positions it as an attractive candidate for further exploration 。 While challenges remain ， particularly concerning scalable synthesis and comprehensive biological evaluation ， ongoing advancements in synthetic methodologies ， computational modeling ， and omics technologies are poised to unlock new opportunities for harnessing this compound's therapeutic promise。

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)